KIMERA-VASC™

Component A: • Sulfobutylether β cyclodextrin (SBE β CD) • 100 mg lyophilized vial (included per complex as shown) Component B: • Selectable peptide signaling component supplied as a separate lyophilized reagent • Variant dependent peptide options include: GHK, KPV, BPC 157, TB 500, MOTS C, Epithalon Important labeling note: The image and description specify the SBE β CD amount. The peptide vial amount is variant dependent and may be listed on the specific complex selection page or vial label.

• Component A: • Sulfobutylether β cyclodextrin (SBE β CD) • 100 mg lyophilized vial (included per complex as shown) Component B: • Selectable peptide signaling component supplied as a separate lyophilized reagent • Variant dependent peptide options include: GHK, KPV, BPC 157, TB 500, MOTS C, Epithalon Important labeling note: The image and description specify the SBE β CD amount. The peptide vial amount is variant dependent and may be listed on the specific complex selection page or vial label.

KIMERA-VASC™ is evaluated as a combined research system rather than a single active compound. Each component contributes to research relevant pathway control: • SBE β CD: widely used in research as a cholesterol and lipid interacting cyclodextrin, commonly applied to modulate membrane lipid availability and lipid stress variables in controlled models • Peptide signaling component: a selectable peptide used to represent distinct signaling contexts, allowing researchers to hold the lipid stress manipulation constant while varying the biological cue Because the reagents are supplied separately and combined immediately prior to experimental use, investigators can control timing, ratios, and sequence, which is often critical in remodeling and adaptation study designs.

KIMERA-VASC™ is commonly examined in laboratory research related to: • Lipid stress and vascular adaptation models where membrane lipid handling is a primary variable • Endothelial signaling and barrier related readouts after controlled lipid environment shifts • Structural remodeling paradigms assessing how tissue context changes under different signaling cues • Comparative signaling studies where the cyclodextrin condition is held constant and the peptide cue is the experimental variable • Multi step remodeling workflows that separate environmental change from repair or signaling phases

Reported observations are model and concentration dependent and may include: • Membrane disruption signals at higher cyclodextrin exposures, which can confound interpretation if cytotoxicity becomes a dominant variable • Non linear responses where small changes in concentration or exposure timing produce disproportionate effects on lipid and signaling readouts • Attribution challenges because outcomes can be driven by lipid manipulation, peptide signaling, or their interaction, requiring appropriate controls

KIMERA-VASC™ is often explored alongside interventions that overlap with its primary pathway themes: Lipid manipulation overlap: • Other cyclodextrins, lipid extraction tools, membrane active detergents, or strong surfactants can stack with SBE β CD effects and confound membrane integrity endpoints Endothelial and remodeling overlap: • Growth factor rich conditions, strong inflammatory stimuli, or matrix remodeling comparators can dominate signal and obscure peptide specific effects within the platform Design and timing considerations: • Sequence matters. Introducing the peptide cue before, during, or after lipid manipulation can produce different readouts, so timing should be treated as a first class variable in protocol design